Profile data is unavailable for this security.
About the company
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-8.40m
- Incorporated2018
- Employees7.00
- LocationOKYO Pharma LtdFloor 4, 14/15 Conduit StLONDON W1S 2XJUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://okyopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immuneering Corp | 0.00 | -53.47m | 48.63m | 68.00 | -- | 0.530 | -- | -- | -1.89 | -1.89 | 0.00 | 3.09 | 0.00 | -- | -- | 0.00 | -47.54 | -- | -51.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Ocuphire Pharma Inc | 19.05m | -9.99m | 49.38m | 14.00 | -- | 0.9561 | -- | 2.59 | -0.4735 | -0.4735 | 0.8727 | 2.08 | 0.3701 | -- | 5.30 | 1,360,643.00 | -19.40 | -58.31 | -20.77 | -65.94 | -- | -- | -52.42 | -137.92 | -- | -8.46 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Modular Medical Inc | 0.00 | -16.76m | 49.89m | 37.00 | -- | 8.92 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
| Odonate Inc | 0.00 | -102.07m | 50.02m | 137.00 | -- | 1,844.41 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Correlate Energy Corp | 7.56m | -12.79m | 50.15m | 19.00 | -- | -- | -- | 6.63 | -0.3554 | -0.3554 | 0.21 | -0.0877 | 2.22 | -- | 13.19 | 398,051.60 | -375.16 | -315.47 | -- | -- | 18.27 | 15.42 | -169.09 | -201.03 | -- | -0.7239 | 8.30 | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| Hcw Biologics Inc | 2.84m | -24.99m | 50.31m | 45.00 | -- | 3.56 | -- | 17.70 | -0.6953 | -0.6953 | 0.0791 | 0.3737 | 0.0755 | -- | 2.91 | 63,150.89 | -66.37 | -- | -78.58 | -- | 19.72 | -- | -879.53 | -- | -- | -90.86 | 0.319 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 50.93m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
| OKYO Pharma Ltd | 0.00 | -8.40m | 51.35m | 7.00 | -- | -- | -- | -- | -10.84 | -10.84 | 0.00 | -0.0178 | 0.00 | -- | -- | 0.00 | -232.28 | -- | -393.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -55.13 | -- | -- | -- |
| Journey Medical Corp | 79.18m | -3.85m | 51.41m | 58.00 | -- | 3.50 | -- | 0.6493 | -0.3502 | -0.3502 | 4.19 | 1.05 | 0.8701 | 2.19 | 3.65 | 1,365,190.00 | -4.23 | -- | -10.51 | -- | 66.33 | -- | -4.87 | -- | 1.10 | 0.6863 | 0.4641 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Eyenovia Inc | 3.79k | -27.26m | 51.47m | 57.00 | -- | 5.11 | -- | 13,579.80 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Aadi Bioscience Inc | 24.35m | -65.77m | 52.05m | 74.00 | -- | 0.4948 | -- | 2.14 | -2.44 | -2.44 | 0.9049 | 4.28 | 0.1538 | 0.6779 | 6.63 | 273,640.40 | -41.54 | -50.25 | -48.46 | -56.15 | 88.47 | -- | -270.04 | -473.97 | 4.48 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Intensity Therapeutics Inc | 0.00 | -11.86m | 52.92m | 5.00 | -- | 4.02 | -- | -- | -0.8653 | -0.8653 | 0.00 | 0.9601 | 0.00 | -- | -- | 0.00 | -110.62 | -- | -254.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Enzo Biochem Inc | 32.80m | -23.31m | 53.27m | 179.00 | -- | 0.7419 | -- | 1.62 | -0.4699 | 0.6708 | 0.6586 | 1.40 | 0.3738 | 1.61 | 4.10 | 183,257.00 | -26.56 | -12.21 | -39.50 | -15.79 | 42.17 | 37.09 | -71.07 | -18.76 | 2.89 | -- | 0.0476 | -- | -4.85 | -21.01 | -23.02 | -- | 7.89 | -- |
| Gain Therapeutics Inc | 55.18k | -22.27m | 53.43m | 29.00 | -- | 3.81 | -- | 968.36 | -1.74 | -1.74 | 0.0042 | 0.7761 | 0.0026 | -- | 0.2544 | 1,902.76 | -104.28 | -- | -132.41 | -- | -- | -- | -40,354.33 | -13,827.07 | -- | -- | 0.0432 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Data as of May 03 2024. Currency figures normalised to OKYO Pharma Ltd's reporting currency: US Dollar USD
2.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Barclays Bank Plc (Private Banking)as of 31 Dec 2023 | 758.33k | 2.28% |
| G1 Execution Services LLCas of 31 Dec 2023 | 34.78k | 0.11% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 13.85k | 0.04% |
| Cerity Partners LLCas of 31 Dec 2023 | 12.31k | 0.04% |
| Geode Capital Management LLCas of 31 Dec 2023 | 12.09k | 0.04% |
| HSBC Bank Plc (Broker)as of 31 Dec 2023 | 11.93k | 0.04% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 11.80k | 0.04% |
| UBS Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Citadel Securities LLCas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
